Yamin Khan, chief executive of Open Orphan PLC (AIM:ORPH, OTC:OPORF), sat down with Proactive London to discuss hVIVO, one of its subsidiaries, signing its first phase 2 field study contract.
It's the first study it has been awarded in the phase 2 arena, according to Khan.
Khan added that these types of studies are beneficial to the company because it will allow them to use nearly 80% of the volunteers, who are generally healthy, in other studies.